Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.

@article{Chang2004RhabdomyolysisWH,
  title={Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.},
  author={Jennie T Chang and Judy Staffa and M. H. Parks and Lanh Green},
  journal={Pharmacoepidemiology and drug safety},
  year={2004},
  volume={13 7},
  pages={417-26}
}
CONTEXT Elevated total cholesterol (total-C) and low-density lipoprotein cholesterol (LDL-C) levels are established risk factors for cardiovascular disease (CVD). HMG-CoA reductase inhibitors (statins) are effective cholesterol-lowering drugs that are commonly prescribed to treat this condition. These drugs are often combined with another class of drugs, fibric acid derivatives, to lower both cholesterol and triglyceride levels. Rhabdomyolysis is a known, rare serious side effect of statin… CONTINUE READING